Uterine Lavage to Screen BRCA Carriers for Ovarian Cancer Risk

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial uses a non-surgical uterine lavage procedure performed before the participant's risk-reduction surgery to collect cells from the fallopian tubes. Collected samples undergo molecular analysis to identify genetic changes associated with progression toward ovarian cancer. Participants have pathogenic BRCA1 or BRCA2 variants and are undergoing standard risk-reduction surgery, with data gathered through sample analysis and a brief survey. The study aims to determine if this lavage-based approach can provide early indicators of cancer development and inform future screening strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \> 18 years of age
* Have a pathogenic BRCA1 or BRCA2 germline variant
* Planned risk-reduction surgery
* Presence of uterus and at least one fallopian tube

Exclusion Criteria:

* Prior tubal ligation
* Prior history of known ovarian or endometrial cancer

Where it's running

• Fred Hutch/University of Washington Cancer Consortium
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Barbara Norquist, MD — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: Intake Coordinators
• Email: swisherlabrc@uw.edu
• Phone: 206-616-3913

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing Olaparib with or without Bevacizumab for Ovarian Cancer Treatment

  This study is testing if a new cancer treatment called olaparib, alone or with another drug called bevacizumab, can help women with advanced ovarian cancer live longer without their cancer getting worse.

  Recruiting at 682 sites Phase 3 NRG Oncology · Birmingham, Alabama and 708 other locations · NCT06580314

• Using Atovaquone to treat platinum-resistant ovarian cancer

  This study is testing if atovaquone, a medication usually used for infections, can help people with platinum-resistant ovarian cancer live longer and feel better.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT05998135

• Universal newborn hearing screening in Kenya using smartphone tests

  This study tests whether smartphone hearing screening can help identify ear infections and hearing loss in infants, including those exposed to HIV, over 6 months.

  Recruiting University of Washington · Nairobi · NCT07879326

• Greek Connections Program to nudge Greek members toward alcohol-free social activities

  This study tests whether increasing alcohol-free social events among fraternities and sororities can reduce heavy drinking and related problems in college students.

  Recruiting University of Washington · Seattle, Washington · NCT07839026

• Spinal Stimulation During Walking to See If Spasticity Lessens in Cerebral Palsy

  This study tests whether walking with non-invasive spinal stimulation reduces leg muscle tightness and improves walking in children and young adults with cerebral palsy.

  Recruiting University of Washington · Seattle, Washington · NCT07826494

• KABAWIL: Reducing Stigma for Indigenous Men and Healers in Guatemala

  A culturally tailored program called KABAWIL will be tried to see if it can reduce HIV-related and intersectional stigma and help Indigenous men and healers engage more with HIV prevention and care in Guatemala.

  Recruiting Phase 1 University of Washington · Seattle, Washington · NCT07786441

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.